Country for PR: United States
Contributor: PR Newswire New York
Wednesday, December 07 2022 - 01:00
Turn Biotechnologies Changes Paradigm in Skin Rejuvenation
MOUNTAIN VIEW, Calif., Dec. 6, 2022 /PRNewswire-AsiaNet/ --

    -- Data unveiled at four industry conferences suggest a single ERA treatment
       may be more effective than combination therapies used today
    -- Biomarker analysis demonstrates ERA's regenerative impact on fibroblast 
       proliferation, collagen VII production
    -- eTurna(TM) lipid-based delivery platform proves groundbreakingly 
       effective at reaching targeted tissue
    -- Company to present updated data during January webinar

Turn Biotechnologies, a cell rejuvenation company developing novel mRNA 
medicines to cure untreatable, age-related conditions, released preliminary 
data that show its therapies rejuvenate skin cells more effectively and safely 
than existing treatments.

Photo -

Logo - 

The company's ERA(TM) (Epigenetic Reprogramming of Aging) treatment, precisely 
transported using Turn Bio's proprietary eTurna(TM) lipid-based delivery 
platform, reversed the hallmarks of aging in human skin – something never 
before achieved. The treatment simultaneously increased fibroblasts and 
collagen VII to restore the production of collagen and elastin, and reduced 
inflammation markers, oxidative stress, senescence, and MMPs, proteins 
responsible for skin degradation versus those untreated.

Preclinical data were presented to dermatologists and industry KOLs attending 
four global conferences in the past five weeks: Global Aesthetics Conference in 
Miami; Cosmetic Surgery Forum in Nashville, Tennessee; Beauty Through Science 
in New York City, and The Longevity Summit in San Francisco, California.

"The data suggest we may be close to redefining the care dermatologists can 
provide their patients," said Jill Waibel, a board-certified dermatologist and 
respected regenerative medicine researcher who presented findings at the Global 
Aesthetics Conference. "The potential to improve the quality of patients' skin 
– its elasticity and its ability to heal – could change the future of 
regenerative medicine."

Hema Sundaram, a board-certified dermatologist and noted researcher in 
regenerative medicine and cell science, presented the data at Cosmetic Surgery 

"This early research suggests that ERA could significantly improve the balance 
between key biomarkers of cell aging and cell youthfulness," she said. "From an 
evidence-based perspective, this carries more weight as a rejuvenation strategy 
than efforts to improve a single biomarker. Research of this type may open the 
door to a new paradigm of dermatologic care."

Data were also presented during sessions of the Beauty Through Science 
conference and the Longevity Summit. 

"We believe this promises to be a game-changer for dermatologists, plastic 
surgeons and their patients," said Turn Bio CEO Anja Krammer. "The true 
breakthrough of combining our mRNA-based ERA therapy with our eTurna lipid 
delivery system, for the first time shows reversal from the effects of aging 
and offers an ability to improve the overall quality of the skin."

Turn Bio executives have committed to releasing additional data during a 
January webinar. Details will be announced in coming weeks.


Turn Bio is a pre-clinical-stage company focused on repairing tissue at the 
cellular level and developing transformative drug delivery systems. The 
company's proprietary mRNA platform technology, ERA(TM) (Epigenetic 
Reprogramming of Aging), restores optimal gene expression by combatting the 
effects of aging in the epigenome. This restores cells' ability to prevent or 
treat disease and heal or regenerate tissue. It will help to fight incurable 
chronic diseases. Its eTurna(TM) Delivery Platform uses unique formulations to 
precisely deliver cargo to specific organs, tissues, and cell types

The company is completing pre-clinical research on tailored therapies targeting 
indications in dermatology and immunology, and developing therapies for 
ophthalmology, osteo-arthritis, and the muscular system. For more information, 

Jim Martinez, rightstorygroup or +1 (312) 543-9026

SOURCE  Turn Biotechnologies, Inc.